BackCharles River Laboratories International Overview
Charles River Laboratories International Inc.

Charles River Laboratories International Debt to Equity

Charles River Laboratories International (CRL) has a debt-to-equity ratio of 1.14, above the Healthcare sector average of 0.26.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

1.14

Debt to Equity

1.14

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

Charles River Laboratories International (CRL) FAQ

As of the most recent data, CRL shows a debt-to-equity ratio of 1.14. That is above the Healthcare sector average of 0.26. Scroll down for historical charts and peer comparison views.

The Healthcare sector average debt-to-equity ratio is about 0.26. Charles River Laboratories International is at 1.14, which is higher that average. That is roughly 330.5% above the sector mean. Use the comparison chart on this page to see how CRL stacks up against individual peers as well.

Investors watch CRL's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Charles River Laboratories International's latest reading is 1.14. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this debt-to-equity ratio page, Stockcircle has Charles River Laboratories International's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently 1.14) with ownership activity and broader fundamentals.

The Healthcare average debt-to-equity ratio is about 0.26, while CRL is at 1.14. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.